Bruno Cogliati

This study shows that B cells support tumor-specific CD4 T cells to enhance PD-1 blockade efficacy, but antibody secretion is not necessary for long-term survival.

This study identifies a dietary lipid axis driven by linoleic acid and FADS2 that suppresses antitumor immunity in liver cancer, offering a therapeutic target for immunotherapy resistance.

This study develops an immunocompetent mouse model of virus-induced liver fibrosis and hepatocellular carcinoma using Norway rat hepacivirus.

This study identifies Wnt9b-Sfrp2 crosstalk between endothelial and stellate cells as a driver of fibrosis resolution in MASH using single-cell and spatial profiling.

This study identifies zonation disruption, specifically aberrant β-catenin expansion, as a novel driver of hepatocellular carcinoma in chronic liver disease, revealing a distinct human HCC subtype with therapeutic implications.

This study shows that deleting ZNRF3 and RNF43 in hepatocytes after MASH onset restores liver regeneration and reverses steatosis, inflammation, and fibrosis without causing tumorigenesis or hepatotoxicity.

This study investigates how RvD1 reduces inflammation, cell death, and fibrosis in MASH by targeting Stat1, ER stress, and MMP pathways.

This study evaluates in vivo anti-FAP CAR T therapy for MASH, showing reduced fibrosis and restored liver homeostasis through HSC depletion and immune modulation.